Shaw Group Completes Review of Shield Building's Design

The Shaw Group Inc. (NYSE: SHAW) issued the following statement regarding the U.S. Nuclear Regulatory Commission’s (NRC) news release on the Westinghouse AP1000™ nuclear power plant shield building design.

Yesterday, the NRC gave confirmation to Westinghouse Electric Company, Shaw’s AP1000 Consortium team member, that they have completed their review of the proposed design of the shield building and that the design will require either additional analysis, testing or actual design modifications to ensure compliance with NRC requirements. The NRC further stated that it considers the review of the shield building as proposed to be complete and that it will support the resolution of the remaining issues on the AP1000 amendment application.

“Westinghouse has been working with the NRC for some time reviewing the design of the shield building, which is within Westinghouse’s scope of work. Certain portions of the design have already been addressed, and this expected confirmation from the NRC now allows the remainder of items to be resolved,” said J.M. Bernhard Jr., Shaw’s chairman, president and chief executive officer.

“We believe all issues outlined by the NRC can be addressed from a technical perspective, and the remaining steps of the certification and licensing processes will continue as currently scheduled,” continued Mr. Bernhard. “Westinghouse has indicated they do not expect a delay in the certification of the AP1000 and still expects the first of the plants to be operational by 2016. Shaw remains steadfast in meeting the timely completion of the AP1000 plants ordered by our clients.”

Source: https://theshawgrp.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.